Vivus Inc (VVUS) 4.06 $VVUS
FDA approves weight-loss drug Contrave
AP - 2 mins ago
WASHINGTON (AP) — U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.
Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:45PM CDT
Emergent BioSolutions (EBS) is set to report second quarter 2014 results on Aug 7 after the market closes.
Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:00PM CDT
Horizon Pharma (HZNP) is set to report second quarter 2014 results on Aug 7 before the market opens.
Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 3:35PM CDT
Mylan (MYL) is set to report second quarter 2014 results on Aug 7 before the market opens.
Technical Analysis on Pharma Equities -- Mylan, AVANIR Pharma, Horizon Pharma, VIVUS, and Auxilium Pharma
PR Newswire - Wed Aug 06, 8:10AM CDT
On Tuesday, August 5, 2014, the NASDAQ Composite ended at 4,352.84, down 0.71%, the Dow Jones Industrial Average declined 0.84%, to finish the day at 16,429.47, and the S&P 500 closed at 1,920.21, down 0.97%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health care Sector Index ended the day at 701.26, down 0.89%, while the index has advanced 4.26% in the previous three months. Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: ANVR), Horizon Pharma Inc. (NASDAQ: HZNP), VIVUS Inc. (NASDAQ: VVUS), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free research on these five companies can be accessed at:
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Thu Jul 31, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the second quarter ended June 30, 2014 after the NASDAQ Market closes on Thursday, August 7, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
FDA approves weight-loss drug Contrave
AP - 2 mins ago
WASHINGTON (AP) — U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
VIVUS Reports Second Quarter 2014 Financial Results
Marketwire - Fri Aug 08, 5:25AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the second quarter ended June 30, 2014 and provided a business update.
Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:45PM CDT
Emergent BioSolutions (EBS) is set to report second quarter 2014 results on Aug 7 after the market closes.
Will Horizon Pharma (HZNP) Earnings Miss Estimates in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 4:00PM CDT
Horizon Pharma (HZNP) is set to report second quarter 2014 results on Aug 7 before the market opens.
Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 3:35PM CDT
Mylan (MYL) is set to report second quarter 2014 results on Aug 7 before the market opens.
Technical Analysis on Pharma Equities -- Mylan, AVANIR Pharma, Horizon Pharma, VIVUS, and Auxilium Pharma
PR Newswire - Wed Aug 06, 8:10AM CDT
On Tuesday, August 5, 2014, the NASDAQ Composite ended at 4,352.84, down 0.71%, the Dow Jones Industrial Average declined 0.84%, to finish the day at 16,429.47, and the S&P 500 closed at 1,920.21, down 0.97%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health care Sector Index ended the day at 701.26, down 0.89%, while the index has advanced 4.26% in the previous three months. Investor-Edge has initiated coverage on the following equities: Mylan Inc. (NASDAQ: MYL), AVANIR Pharmaceuticals Inc. (NASDAQ: ANVR), Horizon Pharma Inc. (NASDAQ: HZNP), VIVUS Inc. (NASDAQ: VVUS), and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Free research on these five companies can be accessed at:
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Thu Jul 31, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results for the second quarter ended June 30, 2014 after the NASDAQ Market closes on Thursday, August 7, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
